(HealthDay)—For patients with homozygous familial hypercholesterolemia, evinacumab lowers low-density lipoprotein (LDL) cholesterol levels, according to a study published in the Aug. 20 issue of the New England Journal ...
Aug 20, 2020
0
2
People who are overweight, even if only modestly, are at greater risk of COVID-19 hospitalization, finds a new study led by UCL researchers.
Aug 14, 2020
0
286
A new study is the first to show a food-based approach using clinically-proven diet interventions to lower cholesterol levels, such as Step One Foods, provides significant healthcare cost savings.
Aug 13, 2020
0
2
For decades, high-density lipoprotein (HDL) cholesterol has been dubbed 'good cholesterol' because of its role in moving fats and other cholesterol molecules out of artery walls. People with higher HDL cholesterol levels ...
Jun 22, 2020
0
1
Chinese and Australian researchers have combined studies of more than 170,000 people and found conclusive evidence that regular physical exercise reduces the risk of age-related cataracts, the cause of blindness in an estimated ...
Jun 9, 2020
0
30
Cholesterol levels are declining sharply in Western nations, but rising in low- and middle-income nations—particularly in Asia, suggests the largest ever study of global cholesterol levels.
Jun 3, 2020
2
126
Heart disease patients taking evolocumab in addition to a statin to achieve extremely low levels of cholesterol do not show increased incidence of neurocognitive impairments, including memory loss or reduction in executive ...
May 4, 2020
0
43
In the fight against neurodegenerative diseases such as frontotemporal dementia, Alzheimer's and Chronic Traumatic Encephalopathy, the tau protein is a major culprit. Found abundantly in our brain cells, tau is normally a ...
Apr 2, 2020
0
305
The investigational drug evinacumab reduced low-density lipoprotein (LDL) cholesterol to near-normal levels among patients with a rare cholesterol disorder, meeting the primary endpoint in the first randomized placebo-controlled ...
Mar 30, 2020
0
0
The cholesterol drug alirocumab reduced low-density lipoprotein (LDL) cholesterol by 35.6% compared to placebo in adult patients with homozygous familial hypercholesterolemia (HoFH), according to a phase three clinical trial ...
Mar 30, 2020
0
0
